You are here: Industry Insights > Market News > Orchid Pharma gets EIR from US FDA for its Alathur facility

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

New Products

CBZ-L-Valganciclovir

4-Bromo-3-nitroanisole

PF-680Adjustable Cellophane Tri-dimensiona Overwrapping Machine (with tear type)

2-Chlorophenothiazine

Flibanserin

its control software

Orchid Pharma gets EIR from US FDA for its Alathur facility

expressbpdSeptember 25, 2017

Tag: Orchid Pharma , EIR , US FDA

Favorites

The facility was inspected by the US FDA

Orchid Pharma has received establishment inspection report (EIR) from the US health regulator for its Alathur facility in Tamil Nadu.

The company has received EIR from the United States Food and Drug Administration (US FDA) based on the successful inspection of the active pharmaceutical ingredients (API) manufacturing facility at Alathur. The facility was inspected by the US FDA, Orchid Pharma said in a filing to BSE.

Previous:Zydus Pharma recalls 44,800 bottles of antidepressant in US

Next:Agilent Technologies launches triple quadrupole mass spectrometer in India

InnoCare Announces Approval of Clinical Trial of a Novel ADC ICP-B794 in China

PharmaSourcesJuly 04, 2025

InnoCare Pharmaannounced the approval of the Investigational New Drug (IND) by the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) to conduct the clinical trial of a novel B7-H3 targeted ADC ICP-B794.

CanSinoBIO Launches Pneumococcal Vaccine: An Innovative Choice to Safeguard Children's Health

ACN NewswireJune 20, 2025

LTS and Nualtis Announce Strategic Cooperation to Expand Global Manufacturing Capabilities, Accelerate Market Expansion, and Ensure Customer Success

PR NewswireJune 25, 2025

Orchid Pharma gets EIR from US FDA for its Alathur facility | Pharmasources.com

Hua Medicine Announces at 2025 ADA Scientific Sessions that Dorzagliatin Combined With DPP-4 Inhibitor Shows Promise in Reducing Blood Lipids While Restoring Glucose Homeosta

ACN NewswireJune 23, 2025

Hua Medicine announced today that the Company presented the latest research results of dorzagliatin, its global first-in-class glucokinase activator (GKA), at the 85th Scientific Sessions of the American Diabetes Association (ADA).

久久婷婷国产综合精品,久久久久久久性潮,换脸国产av一区二区三区,韩国精品一区二区三区无码视频 ,久久久久成人精品无码

Orchid Pharma gets EIR from US FDA for its Alathur facility

Related News

InnoCare Announces Approval of Clinical Trial of a Novel ADC ICP-B794 in China

CanSinoBIO Launches Pneumococcal Vaccine: An Innovative Choice to Safeguard Children's Health

LTS and Nualtis Announce Strategic Cooperation to Expand Global Manufacturing Capabilities, Accelerate Market Expansion, and Ensure Customer Success

Hua Medicine Announces at 2025 ADA Scientific Sessions that Dorzagliatin Combined With DPP-4 Inhibitor Shows Promise in Reducing Blood Lipids While Restoring Glucose Homeosta

You may like
More>>

久久婷婷国产综合精品,久久久久久久性潮,换脸国产av一区二区三区,韩国精品一区二区三区无码视频 ,久久久久成人精品无码

Orchid Pharma gets EIR from US FDA for its Alathur facility

Related News

InnoCare Announces Approval of Clinical Trial of a Novel ADC ICP-B794 in China

CanSinoBIO Launches Pneumococcal Vaccine: An Innovative Choice to Safeguard Children's Health

LTS and Nualtis Announce Strategic Cooperation to Expand Global Manufacturing Capabilities, Accelerate Market Expansion, and Ensure Customer Success

Hua Medicine Announces at 2025 ADA Scientific Sessions that Dorzagliatin Combined With DPP-4 Inhibitor Shows Promise in Reducing Blood Lipids While Restoring Glucose Homeosta

You may likeMore>>

You may like
More>>